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SHORT COMMJUNICATION
Somatic rearrangement of the tropomyosin-receptor-kinase (trk)
oncogene is rare in gastrointestinal cancer
M.F. Fey* & S.L. Thein
Nuffield Department of Clinical Medicine, John Radcliffe Hospital, Oxford OX3 9DU, UK.
Activation of cellular oncogenes plays a major role in the
pathogenesis of malignant neoplasias. Three mechanisms
have been described by which oncogenes can be activated;
these include somatic point mutations in the oncogene itself,
somatic DNA rearrangements and gene amplification
(Bishop, 1987).
Recently, a novel oncogene, the tropomyosin-receptor-
kinase (trk) oncogene or oncD was isolated from a human
colonic carcinoma (Martin-Zanca et al., 1986; Pulciani et al.,
1982). Molecular studies showed that the trk-oncogene is
generated by a somatic DNA rearrangement adjoining a
truncated non-muscle tropomyosin locus and a tyrosine-
specific protein kinase locus. This gene rearrangement was
detected as a novel band by DNA probes hybridising to the
breakpoints of the joined loci. Since this novel band was
present only in tumour DNA but not in DNA from normal
colonic mucosa it seems likely that the trk-oncogene was
generated during the development of this particular
carcinoma rather than being an inherited genetic
abnormality.
We were interested in whether the activation of the trk-
oncogene by somatic DNA rearrangement represented a
common feature of various human cancers, particularly
gastrointestinal carcinomas.
The study included 46 cases of gastrointestinal carcinomas,
a variety of other cancers (5 breast carcinomas, carcinoma
of the urinary bladder and 15 haematological malignancies),
4 colonic adenomas, 4 cases of Crohn's disease and
normal individuals (Table I). The diagnoses of the solid
tumours were made by histological examination of biopsy
material obtained at surgery. The leukaemias were diagnosed
on the basis of peripheral blood films and bone marrow
smears. Samples representing tumour DNA were obtained
from tumour tissue and in case of the leukaemias from
peripheral blood and bone marrow. Constitutional DNA of
the patients was extracted from the following sources:
adjacent normal tissue and peripheral blood leukocytes in
solid tumours and peripheral blood in the lymphoprolifera-
tive disorders. DNA was also extracted from peripheral
blood leukocytes of normal subjects. No constitutional DNA
was available in the 5 cases of leukaemia. All samples were
collected before chemo- or radio-therapy was started.
DNA was extracted from peripheral blood and bone
marrow as described (Maniatis et al., 1982). Solid tissue
material was first ground to powder in liquid nitrogen and
afterwards subjected to the same DNA extraction procedures
used for blood samples. In each case 5jug DNA were
digested with the restriction enzymes EcoRI and BamHI
according to the manufacturer's guidelines. The DNA
fragments were subjected to electrophoresis, constitutional
and tumour DNA in adjacent tracks, in 0.8% (w/v) agarose
gels at 50V for 16h and blotted onto nylon (Hybond-N)
*Present address: Dept. of Medicine, Inselspital, CH-3010 Bern,
Switzerland.
Correspondence: M.F. Fey.
Received 23 September 1987; and in revised form, 26 November
1987.
Table I Cases included in the study
Diagnosis Number ofcases
Carcinoma ofoesophagus I
Carcinoma of stomach 12
Carcinoma ofcolona 24
Adenoma of colon 4
Carcinoma of rectumb 9
Crohn's disease 4
Carcinoma of breast 5
Carcinoma ofurinary bladder I
Hodgkin's disease I
Non-Hodgkin's lymphoma 3
Waldenstroem's disease 2
Multiple myeloma 4
Acute myeloblastic leukaemia (AML) 4
Chronic myelogenous leukaemia 1
Normal individuals 11
Total 86
- malignant neoplasias 67
Colorectal cancer: aDukes' category: A 3; B 12; C 7; D 2; bDuke's
category: A 0; B 5; C 4; D 0; FAB classification of AML: M2 2
cases; M4 1 case; M5 1 case.
filters (Southern, 1975). The filters were hybridised to a
probe derived from the kinase domain of opVcD cDNA, a
1.2kb Ball-EcoRI insert of pDM10-1 (obtained from the
American Type Culture Collection, Rockville, Maryland,
USA, deposited by Martin-Zanca et al., 1986) which was
32P-labelled as described by Feinberg and Vogelstein (1983).
After hybridisation, the filters were washed under stringent
conditions (Old & Higgs, 1983) and autoradiographed at
-70°C with intensifying screens for 3-7 days.
Hybridisation of the pDM10-1 probe with DNA from all
67 cancer patients, the 4 colonic adenomas, the 4 cases of
Crohn's disease and from the normal controls (Table I)
revealed the normal 14kb and 2.3 kb BamHI DNA
fragments and the normal 23kb EcoRI DNA fragment as
described in the original report. A novel rearranged 7kb
BamHI DNA fragment was originally found in a single case
of colonic cancer (Martin-Zanca et al., 1986). However, in
none of our cases was this particular rearranged band or any
other rearrangement seen on autoradiography, despite the
use of an additional restriction enzyme (EcoRI). Over-
exposure of the autoradiographs with respect to the normal
fragments failed to show any faint rearranged bands which
might have been missed after 2-3 days exposure. Figure 1
shows a representative autoradiograph.
The trk oncogene was originally identified as a
transforming gene present in a human colonic carcinoma
and was shown by molecular analysis to be generated by a
somatic gene rearrangement involving a tropomyosin locus
and a tyrosine-specific kinase locus. Gene probes which
recognise sequences within the breakpoints of the two loci
permitted the detection of this rearrangement by DNA
analysis. The fact that it was found only in the tumour DNA
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Figurel1Autoradiograph of constitutional and tumour DNA
from 4 cases of gastrointestinal tumours digested with EcoRI (A)
and BamHl (B) and hybridised to a trk-oncogene probe
(pDM10-1). N =normal mucosa; T =tumour; M =lymph node
metastasis. Cases a and b are rectal and colonic carcinomas,
resp.; cases c and d are gastric carcinomas. The sizes of the
bands are indicated in kilobases. In each case tumour and
constitutional DNA show the normal bands (see text). No
rearranged bands are seen.
but not in the DNA from adjacent normal mucosa strongly
suggested that it was relevant for the development of this
colonic carcinoma (Martin-Zanca et al., 1986). Based on this
report, we studied 12 gastric and 33 colorectal carcinomas as
well as other malignancies to see if the somatic
rearran~gement discussed above is commonly found. None of
our cases showed any rearrangements at the tyrosine kinase
locus. It would, therefore, seem that the activation of the
trk-oncogene by somatic gene rearrangement at this locus
was unique to the tumour described in the original report.
However, it is possible that rearrangements of the locus
might have been detected with the use of restriction enzymes
other than EcoRI and BamHI. The selection of such
enzymes would have to be based on a detailed restriction
enzyme map of the breakpoint region of the tyrosine kinase
locus which is not available in the original report by Martin-
Zanca et al. (1986).
Activation of oncogenes by somatic DNA rearrangement
appears to be rare in human carcinomas. For example, only
4% of human breast carcinomas showed a rearranged c-myc
oncogene (Escot et al., 1986) and no evidence of
rearrangements of c-myc, N-myc, K-ras, N-ras and fos
oncogenes was found in a series of colonic cancers reported
by Alexander et al. (1986). As reported here, activation of
the trk oncogene by genetic rearrangement seems to be
uncommon in gastrointestinal carcinomas. It would appear
that other mechanisms of oncogene activation predominate
in these cancers. Somatic point mutations of ras genes
(particularly c-Ki-ras genes) have been detected in 40% of
colorectal carcinomas (Bos et al., 1987; Forrester et al.,
1987). Amplification of the c-erbB-2 oncogene, an oncogene
resembling part of the gene encoding domains of the
receptor for epithelial growth factor, has been exclusively
found in human adenocarcinomas including carcinomas of
the stomach (Yokota et al., 1986a). Similarly, amplification
of c-myc has been described in colonic cancer, especially in
advanced tumour stages (Alexander et al., 1986; Yokota et
al., 1986b).
In contrast, somatic rearrangements of oncogenes occur
more commonly in lymphomas and leukaemias. For
example, rearrangements of the c-myc oncogene involving a
reciprocal chromosomal translocation with the immuno-
globulin gene loci are found in 100% of sporadic Burkitt
lymphomas (Pelicci et al., 1986). It is not clear as to why
lymphomas and leukaemias should show an apparently
higher frequency of oncogene activation by somatic DNA
rearrangements than carcinomas. Further studies are needed
to establish whether this is a consistent difference between
haematological neoplasias and carcinomas.
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